BC Week In Review | Oct 22, 2012
Company News

AiCuris, Merck deal

AiCuris granted Merck exclusive, worldwide rights to AiCuris' human cytomegalovirus (CMV) portfolio, including letermovir ( AIC246 ). AiCuris will receive €110 million ($142.5 million) up front and is eligible to receive up to €332.5 million ($430.6...
Items per page:
1 - 1 of 1